BioPharma Resources

Drug Trial Radar · NCT06304103

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

An Efficacy and Safety Study of AND017 for the Treatment of Anemia Due to Lower Risk Myelodysplastic Syndromes (MDS)

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Kind Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).

Conditions

  • Myelodysplastic Syndromes

Interventions

  • AND017Drug

    Administer AND017 once per day (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of HI-E/RBC-TI responding subjectsTime frame: From baseline to up to Week 25

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.